The study evaluated the efficacy of treating depressed patients with sulpiride and schizophrenic patients with haloperidol, with or without adjunctive hypothalamic phospholipid liposomes. Results showed that treatment with hypothalamic phospholipid liposomes enhanced the therapeutic efficacy of sulpiride and haloperidol, as measured by greater improvements on diagnostic tests, compared to treatment with the drugs alone. Additionally, the increase in plasma prolactin levels caused by haloperidol was significantly reduced when treated adjunctively with hypothalamic phospholipid liposomes.

1. JEUTICA I
I
l
Num. 1 I
THE EFFEcr OF HYPOTHALAMlC PHOSPHOLIPID LIPOSOMES
IN PAT1ENTS TREATED WITH SmPJRIDE OR HALOPERlOOL
. volume of distribution
5.
E. AGUGLIA, C. CALANDRA, V. RAPISARDA
rnagement of hyperten-
rdy. 15 i
I
ltmittIJe of Ps~çhittt1'1 (Remi 01 Dsp4rlmenl: Pro/. ·V. Rapkaraa)J
Uni'V6'rfiJy of Catania (1141'1)
potassfum conserving / ... D. MAUGERI
23 InJJituie o/ Gero1Jlolccy (Read of Departmento' p.rot. L. Motta),
:>SEI, G. ROMAN8!:LI, UnitJt1rsity o/ Cd/anta (1ta1:y)
IESAN, M. MOTOLESE,
otory heart fa/lure • 31
Summary
of cyprohepladlne and
43 We evaluated the effieacy of treatment with hypothalamic phospholipid
Iiposomes in depressed patieots treated with sulpiride and io schizophrenie
ERICHETII, ":i '.
patients !reated with haloperidol in comp,arison with patients having the
'JJlnical trla! of dihydro·
53
J
. --1.
same disorders and !reated with· the same psychotlopic ~ alone. The
results were assessed nsing the tests of Hamilton, CassllJl(>, Zoog and Witten·
ZAGUI~~k'
, homo Plasma prolactin Ievels were monitored iJr order to detect aetivity of
hypothalamic phospholipids on drng-induced hyperprolactinaemia.
~èute appendlcltls wlth The resu!ts obtained showed not only that the therapeutic association
n of cfif}damycin phos~
of hypotbalamic phospholipid Iiposomes did not negatively inJIuence the
69 therapeutie potentiai of the two. psychotropic drngs, but indeed eohauced
H their efficacy.
mQdul® 200 79
The increase of plasma proIactin levels produced· by sulpiride was not
nog/ycate pressurlsoo modified by treatment with hypothaIamic phospholipid Iiposomes, whereas
89 .~
this increase was conside,ably blunted in patients receiviog haioperid.ol.
'o dlsorders and post-
97 !NTRODUcrION
JOMANGE
'l/meni In tha trt'8tment During Iecent yeaIs pharmacologica1 pIOgICSS has peImitted an improved
..~ .
107 symptomarie ·appIoaeh co mental illnesses. Drugs sueh as haloperidol have
made the control of halincinatory phenomena possible [l}, while drugs sueh
nad/ne In varlous skin
119 a, sulpiride have pIoved to have a good therapeurle effeef in depression, psy.
chosomatic diseases and psychomoror inhibition [2, 3]. Howevèr, tbe pIoblem
of undesiIable side effeets hils remained.
Acta Therapeutica lO (1984) 133
-•..•., - - - - - - - - .
-----:;:te---'-. '

2. i
"'--"--+:.,-
.._.... __.-....._ _. _ - -
J
B. AGUGLIA, C. CALANDRA, n. MAUGERI. V. RAPISAR:OA i
I
Morot side effecrs can be largely controlled by the use cri anrlcholinergic phtenia. The 15 depressed :
!
!
druga, but these do nOt have the same acrion on othet side effeets which to diffetent therapeutic proI
depend on a neuro·endoctine mechanism [4, 5). Recent data in the literarure
have shown that phospholipids can interiere witli this mechanism [61.
. Group A, including i
l(
sulpitide Im. (400 mg pet d I
Mter only seven days of trealment with sulpidde, plasma prolaetin levels
undergo a norable increase. The administtation of haloperidol causeS a rapid
increase in pt;laetin levels afte< only 90 minutes. CASACCHIA [6} has
fot a pedod of 28 da ys; ft. •
hypothalamic phospholipid
administrarion at 8.00 a.m. ,
I
demonstrated that phospholipid Iiposomes may be concemed with tbis in·
crease.
~.
Group B (the control i
received only sulpiride given .
I
Our aim was to evaluate the experimental validìty cri these recent dara.
of 28 days. I
PHOSPHOLIPlD LIPOSOMES
The 15 patìents sufferi I
GtOUP A includìng lO parle
5 patients, 3 women and ; I
The use of thin !ayer chromatography has been able to provide informa- haloperìdol and were treate
don ahoot the chemical struetUre of the various classes of phospholipids.
Interpretation of the cole of the phospholipids has opened up a fascinating Both the sulpitide and
field of tesearch. Phospholipid molecules, when organi2ed in the form cri out period lasring 7 days, ,
Iiposomes, ate able to cross vhe blood-hrain barder [7] and to aet at the psychodiagnostic tests wete ,
level of the centraI nervous system; their effects are as follows : diagnosric tests wete repeate<
- stimulation of the endogenous synthesis of phospholìpids by the activation same assessments were carri
of dddil-transferase;
- activation of adenylcyclase [8];
RESULTS
- increase of the cerebral content of glucose [9, W];
- aerJvation cri the dopaminergic pathways [11, 12].
The deptessed patienrs
Studies by GREGORIADIS [13} and PAPAHADIOPOULOS [14] have esta- values of the various tests. :
blished that the charaeteristic properties of Iiposomes ate related to physical psychodiagnosric tests on ea
stability and the capadty to interaer by fusion with biological membranes. piride and hypothalamie ph
In OUt experiments we used Iiposomes of hypothalamic origin, charac- with sulpitide alone (Group
terized by the presence of long polyunsaturated hydrocarbon chains and nega-
The score trend evaluo
rlvely charged gtoups.
by means of Cassano's tesI
However, the petcentage in
MATERIALS AND METHODS
liposomes were associated w
the gtOUp treated with sulpil
Thitty padents, age<! 20·52 years, were included in the srudy. Por An even cIearer impr<
psychiatdc diagnosis we used the Research Diagnostic Cdteria (RDC) (15). and Hamilton tests in pat
Psychopathological status was ra<ed by mean of Hamilton's scale, Cassano's phospholipid liposomes tOB
resr and Zung's arociery test for depression and Wirrenborn'$ test for schizo- 15.2 % and 35.1 % respecr:
phrenia. Of these patients, 15 suffered from depression aod 15 ftom schizo- sulpitide alone (Fig. 1).
Acta Therapeutica 10 (1984) Acta Therapeutica 10 (198·
.
"}

3. l
..,.
"!.'·:'
,".;:
':".
c,.
-,."
EFFECT OF"HYPOTHALAMIC "PHOSPHOUPID LlPOSOMES
ed by the use cf antichoIinergic phrenia. The 15 depressed patienrs were divided into 2 groups and subjected
·n On other side effeets whieh ro different therapeutic programmes.
]. Recent data in the literature
.ith chis mechanism [6]. Group A, including lO parienrs, 6 women and 4 men, was treated with
sulpiride Lm. (400 mg per day in 2 administrarions at 8.00 a.m. and 1.00 p.m.)
llpiride, plasma prolactin levels
for a period of 28 days; from the 7th day of treatrnent 400 mg per day of
1 of haloperidol causes a rapid
hypothalamic phospholipid liposomes was also given in a single inrravenous
minutes. CASACCHIA [6] has
administrarion at 8.00 "-m.
'y be concerned with this in- . ,
Group B (the control group) including 5 padenrs,3 women and 2 men,
li vallidity of these recent dara. received only sulpiride giveo in the same way, for the whole observadon perio<!
of 28 days.
The 15 patieors suffering from schizophrenia were divided into 2 groups.
Group A including lO parienrs, 6 women and 4 men, and Group B including
5 parienrs, 3 women and 2 men, were administered with 4 mg per day of
; been able to provide informa-
haloperidol and were rreated in the same way as the depressed padenrs.
rious c1asses of phospholipids.
s has opened np a fasdnadng Both the sulpiride and the haloperidol were administered after a wash-
Len organized in the form of out perio<! lasdng 7 days, at che end of whieh baseline prolactin levels and
barrier [7] and to aet at the psychodiaguosdc tesrs were evaluated. On the 7th day cf treatroent the psycho-
= are as follows :
phospholipids by che aetivation
diagnosdc tesrs were repeated and plasma prolacdn levels were detetInined; the
same assessments were carried out at me end of treatmeot.
[9, lO]; RESULTS
lI, 12].
The depressed padeors in both groups presented very similar haseline
ffADrOPOULOS [14] hav'e esta- values cf the various resrs. Tables I, I! and II! show the scOte rrend from the
osomes are related to physical1 psychodiagnostic tesrs on eaeh occasion both for che group rreated with sul-
;vith biological membranes. piride and hypothalamic phospholipids (Group A) and for the group treated
f hypochalamic origin, charac- with sulpiride alone (Group B).
hydrocarbon chains and nega-
Tbc score tread evaluated on the 7th day "'ld, at the end of trearment
by means of Cassano's test revealed a Clear imprb'vemeot in boch- groups.
Howevet, the percentage improvernent in the group in V{hich phospholipid
liposomes were associated with the sulpiride was as high as 16.2 %, while in
che group treated with sulpiride alone it was 8.7 %.
, included in the stiIdy. For An eveo clearer improvemeot was found in the resulrs of boch Zung
<gnostic Criteria (ROC) [15]. and Hamilton tesrs in padenrs who bad been treated wich hypothalamic
of Hamilton's scalIe, Cassano's phospholipid liposomes together with sulpiride. This improverneot was of
I Wittenborn's test for schizo- 15.2 % and 35.1 % respecrively, against the 6 % and 17.7 % achieved with
epression and 15 from schizo- sulpiride alone (Fig. 1).
Acta Therapeutica lO (1984) Acta Therapeutica lO (1984) 135
--"+"--'

4. El
E. "AGUGLIA; C. CALANDRA, D. MAUGBRI. V. RAPISARDA
,
. 1-.
t·
,
i
.'.. TABLE II: S:ore "end jrom Zur.
.phoJpholipid JipOJO'I7WJ
TABLE I: $&01'8 J1'fma tram CatJlJtJ<l.J test {or JepreISeJ p4lients weated with JUlptride Ima
_..pbosphòlipid liposr;nu,s (G...p A) mul sulpirnte oIcn. (&aup B).
.: .~:
GROUP A
Initials Age
IniU.I, Age Baseline Day 7 End of treatment B.L. 37
C.V. 33
B.L. 37 50 74 49
A.R. 32
C.V. 33 99 46 38
B.R. 52
A.R. 32 93 40 45
e.R. 36
B;R. 52 60 38 43
Cur. 37
e.R. 36 64 60 42
e.G. 41
Curo 37 90 60 43
Costo 20
e.G. 41 95 95 84
R.e. 20
Costo 20 60 41 45
M.G. 49
R.C. 20 77 79 63
M.G. 49 98 92 72 I
.. l : Means
. Means 78.6 62.5 52.4 i
_ L:
± S.D.
± S.D. 18.63 21.5 15.3 r
j
GROUP B I
I Initials Age
Day 7
j ..
IniUals A8e BaseUne End of trcatment A.L. 29
I M.G. 43
A.L. 29 86 88 81 I 38
T.G.
M.G. 43 75 71 .- 6S
V.A. 32
·T.G. 38 62 58 54
P.G. 41
V.A. 32 92 84 76
P.G; 41 84 80 72 Means
.. , ± S.D.
Means 79.8 76.2 69.6
. ;
± S.D. ·11.67 11.19 10.5
I
i,.
I
,"
!
!
Acta Therapeutica lO (198'
136 Acta Therapeutica lO (1984)

5. EFFEcr OF .HYPOTHALA,MIC PHQSPHOLIPID LIPOSOMES
<DA
TABLE II: $&o1'e weml tram Zun~s test lor àep1'(JiSQJ, pt1tiqnts 'rea/ed. w;th sulpiriJe atul
phospholipit! Uposomus (Gt-Ofl.P A) and sù/pi;;de tlkntl (.Group B).
l patiemts trealeJ 'lUi/h Ju/piride Ima
p;rid. .Jcn. ( Group B).
GROUPA
lnitials Age Baseline Day 7 En~ or trcatment
)ay7 End of treatment B.L. 37 38 55 30
C.V. 33 56 37 30
74 49
A.R. 32 63 25 36
16 38
B.R. 52 52 33 30
lO 45
e.R. 36 47 38 33 i
18 43
Curo 37 40 48 3g
;O 42
;O e.G. 41 58 53 50
43
Costo 20 31 38 29
15 84
Il 45
R.e. 20 65 62 so
19
12
63
72
·I·"i·
"'"
M.G.
Means
49 67
52.7
56
44.5
51
37.7
I
52.5
11.5
52.4
15.3
l'. ± S.O. 12.34 11.95 9.17
I
l '"
..•.
?: lnitials Age
GROUP B
BaseIine Day 7 End of treatment
I
[
·Il~
)ay7 End of treat.ment A.L. 29 43 48 39
M.G. 43 68 63 56
18 81
T.G. 38 51 45 41
'I 65 i:
;8 54
V.A. n ·62 57 49
'1 ' P.G. .41 37 35 34
14 76 -:.::.
IO 72 Means 52.2 49.6 43.8
± S.O. 12.87 10.85 8.70
'6.2 69.6
'1.19 10.5
..:1...
:1 Acta Therapeutica lO (1984) 137
Acta Therapeutica lO (198~__'_-":i~lr"_

6. . l'r:.
o
j, ... _--_._~-
I E. AGUGl:.IA. C. CALANDRA, D. :M'AUGERI. V. RAPISARDA E
I
I
30
TABLE III: S&o~e trend from Hamil/(m.JJ test far Jepresml p8tìents J1'eatea with su/ijirid(l
ami i'hospholipid Iiposomes (Gro"" A) ami ndpiriJ, al.ne (Group B).
. 20 Clssan
16.ZO/.
GROUPA
..
lnitials BaseIi~e 10
, Age J}ay7. End or treatment
i
, B.L.
C.V.
37
33
11
33
12
15
5
7
l
,[ A.R.
B.R.
32
52
30
19
IO
8
8
2 ~ Sulpi
, C.R. 36 23 12 8
Curo , 37 38 23 7 O Sulpi
C.G. I 41 33 28 28
CeSt. 20 15 16 14
R.C. 20 12 IO 9 Percentage improvement in
M.G. 49 30 31 19
Means 24.4 16.5 10.7
"'s.o. 9·70 8.05 7.7
·GROUP B
100
InitiaIs Age Baseline Day 7 End or treatment
80
A.L. 29 32 28 23
M.G. 43 26 2S 18 60
T.G. 38 23 26 16 !
V.A. 32 19 21 16 40
P.G. 41 27 24 20
" .1 20
•
Means
'" S.O.
25.4
4.82
24.8
2.58
18.6
2.96 ng/ml • E
-.-'
Trend of plasm
138 Acta Therapeulica lO (1984) Acta Therapeulica lO (198'
.::~
'i
X
,,::--.;!..
•<'

7. .RDA
EFFECT QP HYPOTHALAMIC PHOSPHOLIPID LIPOSOMES
.,'
HamlUon
35.1%
30
rQfS~d pt/tienu /re4leJ. with tulp"itiae
",Ipiride aùJne (Group B).
20
:Jay 7 End of treatment lO
12 S
IS 7
IO 8 "
8 2
12 8
~ 'Sulplride + Phospholipld tiposomes
!3
!8
7 D Sulpiride
28
16 14 ,~;;. Fig...
IO 9 Percencage improvement in the psychodiagnostic tests in tbe 2 8J:oups tA and B)
Il 19 of depressed patients.
6.5 10.7
8.05 7.7
,e
100
lay7 End of treatment ~
80
'8 23 :.i
/
:5 18 60
:6 16
1
~l
:1 16 ' "
40
:4 20 - 20
4.8
2.58
18.6
2.96 "!l/m!
i
B 7' .140 29' 99
Sulpirlde
_:' Sulpiride + Phosphollplds
Fig. 2
T:end of plasma prolactin leye1s in depressed patients.
:1
"
.' .' .' ~, " "I
'cta Therapeutica lO (1984) "T
:1' Acta Therapeutica lO (1984) 139
~--'---t-"""'"

8. B. AGUGLIA, C. CALANDRA; n'",-MAUGERI. V. RAPISARDA
The increase in se"rum l'rolactin levels induced by sull'iride was not i;
~"
influenced by adjuvant treatment with hYl'othalamic l'hool'h,?lipid lil'osomes " ~"
(Fig. 2). ,-'i.';
i.
. ,.:
'o
In the schizol'hrenic l'atients treated with haloperidol, the evaluation '}"
of the syml'tomatological trends was carriecl out by means of Wittenborn's
test. The l'rolaetio trend was also evaluated. Table IV shows the values oh·
tained using thls test on the various examinations carried out on the two groul's
of patients. In the l'atients who had undergone adjuvant theral'y with phos.
l'holil'id Iiposomes, a statistically sigoificant iml'rovement was found in 7 of
'·the 9 subtests with the.,Wlttenhorn test. The. iml'rovement obtained was
sigoificant in only one of the sub-tests in l'atients treated with haloperidol
alone.
A global evaluation bf the sub-tests a1so revealed a greater pereentage
iml'rovement in the l'atients treated with l'hool'holipid liposomes (Fig. 3).
In addition, in tbe schizol'hrenic l'arients treated with both haloperidol
. "'and hypothalamic l'hospholil'id Iiposomes the plasma l'rolactin levels tended
-.-;".
to decrease, wbile in the patients treared with haloperidol alone they continued
to increased (Fig. 4).
29.55%
39·
20
lO
~
O
Haloperidol
Haloperidol
+ Phospholipids
j I-"'-j_~--'-"'_~--,-M.:."',---~,-'
;j
Fig. 3
Percentage improvement in the global value ai the Wittenbom test. ù:;Èo:;Èui:;È:
CliClia:ip.;~c.h
140 Acta' Therapeutica lO (1984) i
,.

9. ~
~
ii .. '" 0-0
!'l"''''' '" '~
" ,.,. go ....
s-
~
o
» a. ~ -1?-. r:t B :> (b"~ .g (l ~ g -o
.g tl. f.l
~ g- tg..(i g r:o·a s..~ g:"
~. [
':T tr
,. !=l ~ l:S <: _....
t
O"'
(ti ~
a: IO a. .g:a.
ti)
Ste:. "ttrb~(D'_'<:o
~§~"P-.<:=?ì
~ e..-g ~
e. g. p- P-..,
~. [g~:;g&~s:
'g.
B~
~
".
g f O ~
ii S'
&_p-
g il
~ ~
'1~~~8~oJ2.
.....
~~O'::l ~g-~~
$O "'t-.
'g.~
g,~
ì~
...
IO
~ ..., ""' p-
"li
"
~_ &l",
eq. 8.. ;1. ~ " !=i'!;!
"
f~
Q O O
-
~
'i;j8
~ o ~ 'Q
S'!l !:l. ~. fl ~ a. S' "Oa~Ofllo
& "" '" g. ~
a.a.s. :~
.,
O'Q.P-. li: '1 ..... g- O' o g <:l.
'O
~ 'Y,. $2.. ~ la. '{' --g r:r fA" 8 =g
LI o
( ...", .------~_::-- '::,~".
..::' .~;':'; ::::-:-':. ,..,:': i'-': ,.., "r'.·>:·<;,"·
''O" . '"l,'·:: .,;,", o". ,. ,.-.... _·,;"":.:-":,:,." •• ,.'.;::1e.~
TABLE IV: Score "end Irom lflittenborn's test in schizophrenic patients Ireatea wi/h
haloperidol (#fa phospholi'pid uposomcs (Group A) and haloperidol ttlone (Group Bi
GROUPA
Schizophrenic Paranoic Ebepbrenic
Anxiety Hysteria Mania Depression exitabitity Paranoia schizophrenia schizophrenia Obsession
Nam. BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End
S.C. 6 3 3 2 2 2 6 5 4 O O O 7 5 2 3 3 2 3 3 2 7 5 4 2 2 2
S.M. 8 7 5 6 4 4 7 7 5 3 3 4 9 9 6 lO lO 6 lO lO 6 lO lO 6 5 5 4
B.G. 5 5 4 2 l l 1 l l 6 6 3 7 6 5 9 7 4 9 7 4 2 2 l 3 3 2
P.M. 2 2 l 2 l l l O O 4 3 3 6 4 4 8 5 5 8 5 5 4 3 3 2 2 2
F.S. ·8 7 5 5 4 2 3 3 2 5 4 2 7 7 4 8 6 4 8 6 4 4 3 2 3 3 3
C.M. 5 3 2 3 3 2 5 5 2 2 l l 6 5 4 8 7 5 8 7 5 5 5 4 5 5 4
SoN. 4 4 2 2 . 2 1 3 2 2 6 6 5 6 5 5 8 7 5 8 7 5 5 5 4 3 3 3
L.C. 8 5 4 5 5 4 6 4 4 3 3 2· 8 7 4 9 7 3 9 7 3 4 4 3 4 4 3
P.C. 3 3 2 3 2 2 4 3 3 5 5 4 8 7 3 lO 7 4 lO 7 4 6 6 3 3 3 3
Se.C. 3 4 2 2 2 l 3 2 2 4 3 3i 5 5 4 8 5 4 ·8 5 4 3 3 2 1 l l
Means 5.2 4.3 3.0 3.2 2.6 2.0 3.9 3.2 2.5 3.8 3.4 2.7 6.9 6.0 4.1 8.1 6.9 4.2 8.1 6.4 4.2 5.0 4.6 3.2 3.1 3.1 2.7
P ( 0.001 ( 0.05 N.S. N.S. , 0.01 , 0.001 , 0.001 ( 0.01 ( 0.05
GROUPB
.... ;
'
Schizophrenie Paranoic Ebephrenic
Anxiety Hysteria Mania Depressioi exitabiIity Paranoia scbitopbrenia schizophrenia Obsession
Name BL 7 Ena BL. 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End BL 7 End
M.R. 8 6 5 2 l 2 l l l 6 6 4 3 4 5 8 6 7 8 6 7 3 3 2 6 3 3
D.L. 5 3 3 2 2 2 4 3 3 2 3 2 4 4 3 3 l 2 3 3 2 6 5 3 3 3 3
L.A. 3 2 2 2 3 2 6 6 5 O O O 7 7 6 lO 8 8 9 8 6 4 3 2 l l l
L.G. 4 4 2 3 3 l ·1 O O 3 3 3 l 2 l 9 7 5 9 8 7 5 5 4 4 4 3
C.S. 4 5 4 3 4 3 2 3 3 5 4 3 3 2 3 3 3 ·2 4 2 3 4 4 3 2 2 2
Means 4.8 4.0 3.2 2.4 2.6 2.0 2.8 2.6 2.2 3.2 3.2 2.4 3.6 3.8 3.6 6.6 5.0 4.8 .6.6 SA 5.0 4.4 4.0 2.8 3.2 2.6 2.4
P N.S. N.s. N.S. N.S. N.s. N.S. N.S. < 0.01 N.S.
BL = Baseline 7 =Day7 End = End of rreatment N.S. = Not significaoe

10. B. AGUGLIA, c. CALANDRA. D. MAUGERl, V. RAPISARDA
(5] NIEDERER, W., :R.ICHARDS
humour production.
100 (6] CASACCHIA., M., .Mroo, d.;
! BO
POMPEI, P" FJlAJEsE.:
In: Newoendocrine
I A. Agnati Eds., E1s~
I 60
40
_ ....... ...-:. {7] O!U.ANoo, P., CERRrm, F.,
lipids administeJ:ed 1
I 20 ~~
.. ",'" :
[8] LEON, A., TOIiPANO, G. -
into mice brain l'ho:
i ng/ml L.~.:-'
B
__-::::-_-:,:":,,,_-:::::-,:
7 0 14 6
29- 911 .
(9] B'RUNT, A" LEoN. A., Bo}
free glucose in mire.
!
[lO] BRVNC, A., TOFFANO, G., :
! Haloporidoi phatidylserine liposo
Haloporidol + Pbospholipids [I1J POLLERI, A., ROtA!NDI, I
N1NC, A., MURIAUx
Fig. 4 cerebrol dopamine lì
T.rend of plasma prolactin Ievels in schizophrenic pacients. dopaminergic nervot
[12J TOIiPANO, G., !:BaN, A., :
CONCLUSION somes Da the reguJa
Lipids, 81 : 407-41<
[13] GRF.OORIADIS, G. - The ,
The results show a clear improvement in al! patients and they are there- N.w England J. af .
fore in agreement with pub)ished literature on SuIpiride end haloperidoL [14J PAJ>AHADIOPOlJI.OS, D. -
i"' The concurrent use of hypothalamic phospholipid liposomes does not mode! membranes.
i
, Nonh Holland Pubi
have a negative effect on the therapeutic potential cf the lWO drugs, but
[15J SPITZER, R.L., ENDwon,
; . rather this therapentic effect is strengrhened as shown by the improved results Research Ed., New 'Y
; ;.
i,::
~" obcaìned in the vadous. psychodiagnostic teslS in both depresse<! end schizo-
r··
;" .
i phtenic patients.
With regard to pròlaetin levels, the increase induced by sulpidde was not
Address of the Gbthol': Dr. E.
) .
affected by treatment with phospholipid liposomes; this did how~ver occnr in
RESUME
patients treated with haloperidoL
!.es auteurs ont évalué
thalamiques chez des patie<
BIBLIOGRAPHY
schizophrènes trairés par l'h:
(1] DmVY. P., BoBAN, J., Cou.ARD. J., PJNCHAlU), H. - Etude et expérimentation clini~ ceux observés dans deux gr
ques du RIG25 ou halopeddol. nouveau neuroleptique et neurodysleptique. et traités par les memes agel
A&ta Neurol. PS'Ychi4tf'., Belgi&al 59 : 337 (1959). rée à l'aide des teslS de H:
(2] SARTESCHl. P., CONTI. I.., CAssANo, G.D. - Sulpicide in the ueatment of psychocic plasmatiques en p,olaetine .
and neurotic syndromes. In: Sulpiride and orber benzamides. ltalian Brain
Res. Found. Fress, Milan (1979). mel!e des phospholipides l
[3J ULETI, G.H., HEUSlD., A.F., WOtlD, T.J. - The effects of psychorroplcs drugs on par 105 deux psychotropes.
the EEG af the cbJ:onic psychotic patients. In Application of EEG in PsychiatrY~ le.s résilltats démontrer
Duke Univo P.ress. North Cacolioe (1965). diques hypotbalamiques SUr
(4] F'INx, M. - Quantitative EEG and Human psychopharma.cology. Applica.rion of EEG souS. forme d'un renforcemeJ
in Psychiatry. Duke Univo Press, North Caroline (1965).
142 Acta Therapeutica 10 (1984) Acta Therapeutica lO (]98.

11. EFFECT OF HYPOTHALA'MlC PHOSPHOLIPID LlPOSOMES
DA
[5J NIEDERER, W" RICHARDSON. B.P.• DoNATSCH, P. - Hormonal concrol of aqueous
homour prodnaion. Exp. Eye Ret., 20 : 329 (1975).
(6J CASACClUA., Mo. MEoo. d.:'C:.utCHEDI, F., DI C:EOr.m•.M., F.ALASCHI. P.) Rocco. A..
POMPEI, P., F1w'EsE, G. - Neuroendocrlne side effects of antipsychotic therapy.
In: Neuroendocrine Correlates in Neurology and PsychiattY. RE. Muller and
A. Agfioli Ed,., E!sevier, 211-224 (1979).
_ .. __ ..tIo (7] ORLANDO, P., C'ERRtro, P., ZI!uu.I, P. - The fare of double·lahelled braio phospho-
:~ .. Jipid, admioisrered ro mice. Il Parma"" 30: 451-458 (1975)•.
(8] LEON, A.) TOPFANO) G. -.I!ossible .cole of BCPL in enhanciog 32 1>i iorozporatioo
inro mie< b",in phospholipid. Ad•• Exp. Med. Biol., 72: 307-313 (1976).
[9J BR.UNI, A., !.'EoN. A.• BoA:RA"J1O, E. - .:Bffecr of polar lipids on ccrebral content of
free gluco« in mice. Ad•. Exp. Mad. Bio/., 72 : 271-2g3 (1976).
[lO] BRUNI, A., Topp.A:No, G., l.Eo.N. A.• BoA!R.Aro. E. - Pha.rmacological effects of phoo-
phacidy1serine lipooomes. NaJura, 260 : 331·333 (1976).
holipids [l1J POL'I.ERI, A.• R01AlNDI. E., BA.R!R:EccA. T., GlA!RRossr. R., .M.A'STURZO. P., GAU.A-
A.) MUR.J'ALDO, G., NIZZQ. M.c. - Effeet of b.ra.in phO$pholopids on
NlNl,
cerebral doparnine and on proIacdn serum leveIs. Symposium on non striata!
!ophrenic patients. dopamine.rgic nervous tissue. Foit Village (1976).
[12J TOFFANO, G.• lEoN, A., SAvolNl, G., 01U.AND0. P. - Effea of phospholipid' lipo-
somes 00 the regulacion cf ce.rebral metabolism. pft11&tion 4nd Bi()synthe,Sù of
IJpuu, 81: 407-418 (1977).
[13] G. - The car.rier potential cf Iiposomes in biology and medicine. Thq
GREOORIAOIS,
II patients and they are thet'" Net" Engidnd J. oi Med., 295: 765·770 (1976).
lpiride and haloperidoI. (l4] PAPARADIOPOULOS, D. - Calcium·induced phase change and fusion in nawml and
pholipid lipooomes does nor mode! membranes. In: Membran Fusion. G. Poste' 'RIld G.L. Nicolson BIs.,
North Hnllattd Publi'hio8, Amsrerdam; 765-790"(1978).
:odal of rbe <wo drugs, but
[15J SPrr.2'ER, R.L., EN:ollCOIT, J., ltoBJNs. E. - Reseatch diagnostie criteria. Biometrie
~DWn by the imptoved tesults ReSearch Ed., New York (1977).
n both depressed and scnìzo-
Address of the ailthor: Dr. E. AGUGLIA, Via Etneo, 740, 95128 Catania <Ita/y).
:I
. induced by snlpiride was not
.es; tbis did however occnr in
RESUMB
Les anteurs onr évalué l'efficacité des lipooomes phospbolipidiques hypo-
thalarnlques che>: des patients déprimés traités par le sulpitide et chez des
schizophrènes rraités par l'halopéridol en comparant les résnlrats obtenus avec
- Etude et expérimentatibn clini~ ceux observés dans deux groupes de contròle souffrant des m~mes maladies
J.euroleptique et neurodysleptique. et traités par les m~mes agents psychotropes. La qualité des résultats fut mesu·
'59). rée à l'aide des tests de Harnllton, Cassano, Zung et Wittenborn. Les talIX
.ride in the trearmene of psychoclc plasmariques en prolacclne furenr suivis afin de détecter une influence éven-
other benzamides. Italian Baia
tnelle des phospholipides hypothalamiques sur l'hyperprolaclinémie induite
~ effects of psychotroplcs drugs oa par les deux psychotrQPes.
Applicacion of EEG in Psychlatry, Les résulrats démoiIrrenr une aclion favorable des liposomes phospholipi·
diques hypothalamiques sur les effets thérapeutiques des deux psychotropes
pharmacology. AppHcation cf EEG sous forme d'un renfotcement de leur aetioo.
,lioe (1965).
.cta Therapeutica lO (1984) Acla Therapeutica lO (1984) 143
---_._-_ .